Investors

Webcast Depomed at UBS Global Healthcare Conference  (Replay) 05/21/13 at 10:00 a.m. ET

Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. We currently sell Gralise® (gabapentin), a once-daily product for the management of postherpetic neuralgia, and Zipsor® (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain. We actively seek to expand our product portfolio through in-licensing, acquiring or obtaining co-promotion rights to commercially available products or late-stage product candidates that could be marketed and sold effectively with our existing products through our sales and marketing capability.

We also receive royalties on three products marketed by licensees of our Accuform ® gastroretentive drug delivery technology: Glumetza® commercialized by Santarus, Inc., Janumet XR® commercialized by Merck & Co., Inc. and Nucynta ER® commercialized by Janssen Pharmaceuticals, Inc. We have license and development arrangements relating to product candidates that use our Acuform® delivery technology with Covidien, Ltd., Boehringer Ingelheim International GMBH, Ironwood Pharmaceuticals, Inc., and Janssen Pharmaceutica N.V.

Date Title   05/16/13 Depomed To Present At UBS Global Healthcare Conference 05/08/13 Depomed Reports First Quarter 2013 Financial Results 05/01/13 Depomed To Report First Quarter Fiscal Year 2013 Financial Results On Wednesday, May 8, 2013

Date Title 05/21/13 10:00 a.m. ET Depomed at UBS Global Healthcare Conference Location Sheraton New York Hotel New York, NY US Supporting Materials   UBS Global Healthcare Conference Presentation 05/08/13 4:30 p.m. ET Q1 2013 Depomed Earnings Conference Call Supporting Materials   Depomed Q1 2013 Earnings Conference Transcript 03/19/13 11:30 a.m. PT Depomed at Roth Conference Location Dana Point, CA

• Management
• Board of Directors
• Corporate Governance
• Press Releases
• Analyst Coverage
• Quarterly Earnings
• Webcast and Presentations
• Annual Reports
• SEC Filings
• Fundamentals
• Investor FAQ
• Stock Information